Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer.-MedSci.cn

Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer.

Sharma, MR; Isaac, D; Ramaekers, R; Ridinger, M; Erlander, M; Mendelsohn, L

CANCER RESEARCH, 2021; 81 (13):

科室
- - 订阅+
  - 更多科室
工具
服务